Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The substances may help cancer cells in other ways, too
Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial
GLP-1 Drug Prescriptions Have Doubled in Recent Years, But Many Users Quit Soon After Starting Use of Ozempic, Wegovy, Mounjaro and other GLP-1 drugs has spiked in recent years due to their effectiveness promoting weight loss, but side effects often cause users to discontinue the treatment within the first year
Lifestyle factors Busy schedules often favor weekly weight loss shots rather than daily injections
Ozempic and Mounjaro are approved to treat type 2 diabetes but can also lead to weight loss
Those timelines are estimates, not guarantees, and regulatory review can extend considerably depending on the data package Eli Lilly submits and FDA's review queue
